Other equities research analysts have also recently issued reports about the stock. Citigroup raised shares of MEDNAX from a neutral rating to a buy rating and set a $34.88 price objective for the company in a research report on Monday, January 14th. They noted that the move was a valuation call. Zacks Investment Research raised shares of MEDNAX from a sell rating to a hold rating in a research report on Monday, January 28th. Deutsche Bank started coverage on shares of MEDNAX in a research report on Thursday, January 3rd. They issued a hold rating and a $34.00 price objective for the company. BMO Capital Markets lowered their price objective on shares of MEDNAX from $48.00 to $43.00 and set a market perform rating for the company in a research report on Friday, November 2nd. Finally, Robert W. Baird lowered their price objective on shares of MEDNAX from $48.00 to $40.00 and set a neutral rating for the company in a research report on Friday, November 2nd. Three analysts have rated the stock with a sell rating, eight have assigned a hold rating and three have issued a buy rating to the stock. The stock presently has an average rating of Hold and a consensus target price of $44.57.
MEDNAX stock opened at $34.35 on Friday. The stock has a market capitalization of $3.14 billion, a price-to-earnings ratio of 9.79, a P/E/G ratio of 0.89 and a beta of 0.69. The company has a debt-to-equity ratio of 0.64, a current ratio of 1.40 and a quick ratio of 1.43. MEDNAX has a 1 year low of $31.68 and a 1 year high of $63.04.
In other news, insider John C. Pepia sold 2,500 shares of the business’s stock in a transaction dated Tuesday, January 22nd. The shares were sold at an average price of $36.60, for a total value of $91,500.00. Following the completion of the sale, the insider now owns 28,583 shares in the company, valued at approximately $1,046,137.80. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Insiders own 2.70% of the company’s stock.
Large investors have recently bought and sold shares of the company. GHP Investment Advisors Inc. raised its holdings in shares of MEDNAX by 19.8% in the 3rd quarter. GHP Investment Advisors Inc. now owns 9,775 shares of the company’s stock valued at $456,000 after purchasing an additional 1,615 shares in the last quarter. Ardevora Asset Management LLP bought a new stake in shares of MEDNAX in the 3rd quarter valued at about $9,892,000. Eagle Boston Investment Management Inc. raised its stake in shares of MEDNAX by 5.2% during the 3rd quarter. Eagle Boston Investment Management Inc. now owns 257,103 shares of the company’s stock worth $11,996,000 after acquiring an additional 12,595 shares in the last quarter. Oakbrook Investments LLC raised its stake in shares of MEDNAX by 33.3% during the 3rd quarter. Oakbrook Investments LLC now owns 11,600 shares of the company’s stock worth $541,000 after acquiring an additional 2,900 shares in the last quarter. Finally, Panagora Asset Management Inc. raised its stake in shares of MEDNAX by 1,005.5% during the 3rd quarter. Panagora Asset Management Inc. now owns 38,274 shares of the company’s stock worth $1,786,000 after acquiring an additional 34,812 shares in the last quarter. Institutional investors and hedge funds own 99.76% of the company’s stock.
MEDNAX Company Profile
MEDNAX, Inc, together with its subsidiaries, provides newborn, anesthesia, maternal-fetal, radiology, pediatric cardiology, and other pediatric subspecialties physician services in the United States and Puerto Rico. It offers neonatal care services, such as clinical care to babies born prematurely or with complications within specific units at hospitals through neonatal physician subspecialists, neonatal nurse practitioners, and other pediatric clinicians; anesthesia and anesthesia subspecialty care; and acute and chronic pain management services.
Featured Article: Candlestick
Receive News & Ratings for MEDNAX Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MEDNAX and related companies with MarketBeat.com's FREE daily email newsletter.